Rose Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merz gains Radiesse wrinkle filler

Executive Summary

German drug company's $253 mil. acquisition of California-based BioForm Medical, announced Jan. 4, provides it with latter's FDA-approved Radiesse wrinkle filler, rounding out its aesthetic product offering and accentuating its presence in the U.S. Merz's pre-acquisition aesthetic portfolio included dermal fillers Belotero (hyaluronic acid) and Novabel (alginate), both available in Europe and undergoing trials to support U.S. approval. Sales of Mederma anti-scarring creams have helped support the firm's U.S. business (1"The Rose Sheet" July 20, 2009). Made of smooth calcium hydroxylapatite microspheres suspended in a gel and designed to stimulate production of new collagen as a patient's own soft tissue replaces the gel carrier, Radiesse competes against Allergan's Juvederm, Medicis' Restylane and Johnson & Johnson's Evolence, among others. BioForm booked sales of about $66.5 mil. in fiscal 2009. Following completion of the acquisition, which Merz expects in March, the firm will relocate its U.S. aesthetics business to BioForm's San Mateo, Calif., headquarters and the combined operation will be renamed Merz Aesthetics
Advertisement

Related Content

Mederma Anti-Scarring Targets Stretch Marks With New Cream
Mederma Anti-Scarring Targets Stretch Marks With New Cream
Advertisement
UsernamePublicRestriction

Register

RS016656

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel